ZIOPHARM Oncology, Inc. News
I Spotted a Below-the-Radar Shift
Let's check out why rising rates aren't bothering big-cap tech and growth stocks; also, let's check in on DIS and sentiment.
Speculation Is Back
Very little changed on the market today, but here's what Nasdaq’s soaring volume could be telling us.
Why 2018 will be better for biotech deals than 2017
Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.
Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI
Here's what you need to know now for Monday, Jan. 22.
Immunotherapy stocks power higher on Celgene-Juno deal
Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.
More Immunotherapy Buyouts Likely After Kite Sale
More Immunotherapy Buyouts Likely After Kite Sale
Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views
Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.
Judgment Day; Good, Bad and Ugly: Doug Kass' Views
Doug Kass shares his thoughts on whether Judgment Day is here for the financials and discusses General Electric, Apple and Caterpillar.
Twitter, Netflix, MetLife: Doug Kass' Views
Doug Kass shares his thoughts on Twitter and talks about Sears.
Biotechs Among 5 Stocks Setting Up for Major Breakouts
Here's how to rake in the profits off some potential big breakouts.
Breaking News
Target Brings New Designer Brands to Its Stores
Target brings in a famous partner to expand designs.
Chick-fil-A Offers a New Dining Experience
Chick-fil-A is offering more variety in a new concept.
Billionaire Gautam Adani Loses $26 Billion
The Indian tycoon and his empire are facing allegations of fraud by an American short-seller. Their answer does not convince investors for the moment.
Elon Musk Has Questions About the War in Ukraine
The billionaire had proposed a controversial plan to end the Russia-Ukraine conflict, which now has lasted nearly a year.